Mirian Brink (M Brink)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 15

Top Topics

Newly Diagnosed

Chemotherapy Induced

Prognostic Factors

Ejection Fraction

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Mirian Brink, Francien Huisman, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J S H Sherida Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry. Blood advances 8 (14) (2024)
A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
Mirian Brink, Francien Huisman, Frederik Okko Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Marielle J Wondergem, Lara H Bohmer, F J S H Sherida Woei-A-Jin, Otto J Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin A Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry. Blood advances (2024)
A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
Mirian Brink, Francien Huisman, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J S H Sherida Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry. Blood advances 8 (14) (2024)
A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
Mirian Brink, Francien Huisman, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J S H Sherida Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry. Blood advances 8 (14) (2024)
Johanna A A Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H Tonino, Joost S P Vermaat, Martine E D Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J Plattel, Mirian Brink, Marcel Nijland
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics. Blood cancer journal 13 (1) (2023)
Mirian Brink, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Pim G N J Mutsaers, Lara H Böhmer, F J S H Sherida Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Wouter J Plattel, Gerwin A Huls, Joost S P Vermaat, Marcel Nijland
Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood 140 (9) (2022)
Mirian Brink, Monique C Minnema, Otto Visser, Mark-David Levin, Eduardus F M Ward Posthuma, Annemiek Broijl, Pieter Sonneveld, Marjolein van der Klift, Wilfried W H Roeloffzen, Matthijs Westerman, Cleo R van Rooijen, Paulus A F Geerts, Sonja Zweegman, Niels W C J van de Donk, Avinash G Dinmohamed
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. Blood cancer journal 12 (3) (2022)
Diana Al-Sarayfi, Frederik O Meeuwes, Müjde Durmaz, Djamila E Issa, Rolf E Brouwer, Aart Beeker, Anna van Rhenen, Pim G N J Mutsaers, Lara H Böhmer, Marjolein W M van der Poel, Liane Te Boome, Tom van Meerten, Martine E D Chamuleau, Josée M Zijlstra, Mirian Brink, Marcel Nijland
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma. Blood cancer journal 12 (9) (2022)
Mirian Brink, Kaz Groen, Pieter Sonneveld, Monique C Minnema, Annemiek Broijl, Avinash G Dinmohamed, Ellen van der Spek, Mark-David Levin, Paula F Ypma, Esther de Waal, Eduardus F M Ward Posthuma, Sonja Zweegman, Niels W C J van de Donk
Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood cancer journal 11 (11) (2021)
Mirian Brink, Otto Visser, Sonja Zweegman, Pieter Sonneveld, Annemiek Broyl, Niels W C J van de Donk, Avinash G Dinmohamed
First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. Blood cancer journal 11 (2) (2021)
Mirian Brink, Xaver U Kahle, Joost S P Vermaat, Josée J M Zijlstra-Baalbergen, Martine Chamuleau, Marie José Kersten, Müjde Durmaz, Wouter J Plattel, Pieternella J Lugtenburg, Wendy Stevens, Rogier Mous, Elisabeth G E de Vries, Marjolein W M van der Poel, Prashant V Nannan Panday, Gerwin Huls, Tom van Meerten, Marcel Nijland
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood advances 5 (15) (2021)